Guardant Health reported a sharp jump in second-quarter revenue driven by stronger oncology testing volume, with Shield colorectal screening tests scaling and Guardant360 expanding after a June FDA approval. The company tied growth to oncology revenue up 38% year over year and announced that Guardant360 Liquid CDx received FDA clearance in June as a companion diagnostic for Boehringer Ingelheim’s HER2-mutant non-small cell lung cancer therapy. Guardant also pointed to increased adoption support from guideline updates by the American Cancer Society and coverage announcements from UnitedHealthcare for Shield. The update reflects how reimbursement momentum and companion diagnostic label expansions can translate directly into near-term commercial performance for liquid biopsy platforms.